The NMPA Grants Breakthrough Therapy Designation to AusperBio’s AHB-137 for Treating Chronic Hepatitis B
Shots:
- AusperBio’s AHB-137 has received the NMPA’s breakthrough therapy designation for the treatment of chronic hepatitis B (CHB) infection, expediting its development
- The designation was supported by P-I/IIa (China) and P-I (international) studies evaluating the safety & efficacy of AHB-137 for treating CHB infection. Data was highlighted at EASL 2024
- AHB-137 is an unconjugated antisense oligonucleotide (ASO) based on AusperBio's Med-Oligo ASO technology to cure chronic hepatitis B, with its non-clinical data highlighted at the EASL 2023
Ref: PR Newswirew | Image: AusperBio
Related News:- Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
